VYNE Therapeutics (VYNE) EBITDA (2017 - 2026)
VYNE Therapeutics (VYNE) EBITDA from Mar 31, 2017 to Mar 31, 2026. The TTM VYNE Therapeutics (VYNE) EBITDA is -$34M. You can adjust inflation or export chart.
All data is split-adjusted. You can find the most accurate data from the reports on the SEC official website. We recommend verify information using official company filings before making investment decisions.
Annual EBITDA
Quarterly EBITDA
VYNE Therapeutics (VYNE) EBITDA CAGR table
| Period | CAGR |
|---|---|
| 1 Year TTM | -75.03% |
| 3 Years TTM | -28.80% |
| 5 Years TTM | -44.83% |
| All Time TTM | -13.51% |
Annual EBITDA change of VYNE Therapeutics (VYNE)
| Year | EBITDA | Change |
|---|---|---|
| 2026 | -$3.81M | -87.18% |
| 2025 | -$30M | -31.86% |
| 2024 | -$44M | +49.11% |
| 2023 | -$29M | -14.49% |
| 2022 | -$34M | -11.80% |
| 2021 | -$39M | -84.62% |
| 2020 | -$252M | +164.03% |
| 2019 | -$96M | +28.09% |
| 2018 | -$75M | +156.43% |
| 2017 | -$29M | +106.68% |
| 2016 | -$14M | +205.21% |
| 2015 | -$4.61M | N/A |
Comparison VYNE Therapeutics (VYNE) five years EBITDA CAGR with competitors
VYNE Therapeutics (VYNE) five years EBITDA CAGR is -33.53%.